Bridgefront Capital, LLC Anavex Life Sciences Corp. Transaction History

Bridgefront Capital, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$6.55 - $9.37 $16,113 - $23,050	-2,460 Reduced 10.46%	21,047 $137,000
Q2 2023 Aug 14, 2023	BUY	$7.66 - $9.5 $24,320 - $30,162	3,175 Added 15.62%	23,507 $191,000
Q1 2023 May 15, 2023	BUY	$8.32 - $11.75 $169,162 - $238,901	20,332 New	20,332 $174,000
Q3 2022 Nov 29, 2022	BUY	$8.9 - $12.86 $90,904 - $131,352	10,214 New	10,214 $105,000

155

27.3M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $673M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Bridgefront Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgefront Capital, LLC with notifications on news.